A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a novel small molecule inhibitor of
thioredoxin-1, a small protein over-expressed in many human cancers that is associated with
aggressive tumor proliferation, angiogenesis, and drug resistance. This study is being
conducted to determine the maximally tolerated dose of PX-12 delivered as a 72-hour infusion
over days 1, 2, and 3 of a 21-day cycle in patients with advanced or metastatic cancer.